Trial Profile
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 12 Oct 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms PROSPER; PROSPER RCC
- 06 Oct 2023 Planned End Date changed from 30 Nov 2023 to 4 Oct 2024.
- 06 Jun 2023 Results assessing the accuracy and safety of primary tumor core biopsy in predicting final histology and nuclear grade by both site and central pathology review as well as time from enrollment to surgery and also report adverse events of preoperative nivolumab, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 13 Sep 2022 Status changed from active, no longer recruiting to discontinued according to results presented at the 47th European Society for Medical Oncology Congress